ALS Therapy Development Institute Signs Aptabody™ Discovery Agreement with Aptagen
News Jan 08, 2008
Under the terms of the contract, Aptagen will apply its proprietary technology to develop aptabodies™ -- synthetic "molecular bullets" designed to deliver a therapeutic payload to diseased cells.
Aptagen's technology will be used as a research tool to expedite drug development in a leading mouse model of amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease. ALS is a progressive and fatal neurodegenerative disease with no known cause or cure.
The integration of aptabodies into the Institute's arsenal of technology is an integral part of its scientific plan announced in January. Through its collaboration with the Muscular Dystrophy Association's Augie's Quest ALS initiative, the Institute will apply the aptabody technology in investigating the potential of gene therapy for treating ALS.
"The use of aptabody conjugates to target a therapeutic to a specific cell type is a powerful tool that removes some of the limitations of drug delivery that utilize engineered viruses," said Steven Perrin, Ph.D., chief scientific officer at ALS TDI.
"Aptabody drug delivery may reduce some of the inefficient trial and error of developing small molecules that must cross the blood brain barrier to reach their respective targets in the central nervous system," Perrin added.
"Traditional drug discovery strategies against devastating diseases like ALS have been slow to reach the clinic," said Tom Caltagirone, Ph.D., president and CEO of Aptagen. "We are optimistic about ALS TDI's initiative to aggressively explore aptibody technology as a viable solution for rapidly developing successful drug candidates against ALS."
Chemists Design More Efficient Microreactor Using 3D PrintingNews
Researchers developed an electrochemical microreactor using additive manufacturing technology (commonly known as 3D printing). The newly developed microreactor was tested on synthesis of isoindolinones, which are found in many natural products, pharmaceuticals, and biologically active molecules.READ MORE
Novel Chemistry Technique Simplifies Late-Stage Modification of Drug CompoundsNews
Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.READ MORE
Revolutionary Imaging Technique Uses CRISPR to Map DNA MutationsNews
The new high-speed AFM method can map DNA to a resolution of tens of base pairs while creating images up to a million base pairs in size. And it does it using a fraction of the amount of specimen required for DNA sequencing.READ MORE
Comments | 0 ADD COMMENT
3rd Annual NGS Data Analysis and Informatics Conference
Feb 08 - Feb 09, 2018
3rd Annual Genome Editing & Engineering Conference
Feb 08 - Feb 09, 2018